ArticleGastrointestinal cancer research : GCR2008
Liver stem cells and tgf-Beta in hepatic carcinogenesis.
Article in Gastrointestinal cancer research : GCR, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 37 citations in OpenAlex.
- Indirect Mechanisms of Transcription Factor-Mediated Gene Regulation during Cell Fate Changes.Advanced genetics (Hoboken, N.J.) · 2022Article
- Application of Nanotechnology in Targeting of Cancer Stem Cells: A Review.International journal of stem cells · 2019Review
- Review
- Distinctive expression pattern of OCT4 variants in different types of breast cancer.Cancer biomarkers : section A of Disease markers · 2017Article
- Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway.Oncotarget · 2016Article
- Comparative study of the effects of PEGylated interferon-α2a versus 5-fluorouracil on cancer stem cells in a rat model of hepatocellular carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Investigating the functionality of an OCT4-short response element in human induced pluripotent stem cells.Molecular therapy. Methods & clinical development · 2016Article
- TGF-β signaling alters the pattern of liver tumorigenesis induced by Pten inactivation.Oncogene · 2015Article
- Links between cancer stem cells and epithelial-mesenchymal transition.OncoTargets and therapy · 2015Review
- Targeting cancer stem cells by using the nanoparticles.International journal of nanomedicine · 2015Review
- Combinatorial interventions inhibit TGFβ-driven epithelial-to-mesenchymal transition and support hybrid cellular phenotypes.NPJ systems biology and applications · 2015Article
- Article
- Network modeling of TGFβ signaling in hepatocellular carcinoma epithelial-to-mesenchymal transition reveals joint sonic hedgehog and Wnt pathway activation.Cancer research · 2014Article
- Recent insights into hepatic cancer stem cells.Hepatology international · 2014Article
- Deleted in liver cancer 1 expression and localization in hepatocellular carcinoma tissue sections.Oncology letters · 2014Article
- The Role of Snail in EMT and Tumorigenesis.Current cancer drug targets · 2013Review
- OCT4 promotes tumorigenesis and inhibits apoptosis of cervical cancer cells by miR-125b/BAK1 pathway.Cell death & disease · 2013Article
- Resveratrol downregulates interleukin-6-stimulated sonic hedgehog signaling in human acute myeloid leukemia.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- The Inhibitory Effect of 3 β -Hydroxy-12-oleanen-27-oic Acid on Growth and Motility of Human Hepatoma HepG2 Cells through JNK and Akt Signaling Pathway.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- Hepatic stem cells and transforming growth factor β in hepatocellular carcinoma.Nature reviews. Gastroenterology & hepatology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Hepatocellular carcinoma is the fifth most common malignancy worldwide. Recent trends indicate a rising incidence in the United States, with a 5-year survival rate of less than 5%. New therapeutics targeting advanced-stage hepatocellular carcinoma, such as sorafenib, have marginally improved the median overall survival by 3 months. There is an urgent need for new targeted agents that are associated with minimal local and systemic toxicities. Up to 40% of hepatocellular carcinomas are clonal, potentially arising from stem cells and increased activation of multiple pathways including IL-6/STAT3, WNT, CDK4, and hedgehog, as well as loss of response to the transforming growth factor-beta (TGF-beta) signaling pathway. Our hypothesis has been that these "cancer stem cells" or cancer sustaining cells may prove to be strong genetic and therapeutic targets. Modulating stem cell renewal factors such as STAT3, NANOG, and OCT4 may reduce hepatocellular carcinoma formation. These points are discussed in detail in this review.
Identifiers
19343145PMC2661545W170574140What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.